Cancer

·

Study

Mushroom Compounds Flagged as Liver Cancer Drug Candidates

Mushroom Compounds Flagged as Liver Cancer Drug Candidates

What they found

Computer screening found fungal compounds like Phellibaumin A bind strongly to a key liver cancer enzyme.

Computer screening found fungal compounds like Phellibaumin A bind strongly to a key liver cancer enzyme.

How solid is it?

Lab dish

Lab dish

Lab – computational screening

Lab – computational screening

Evidence ladder: Lab dish → Animal → Early human → Strong human. Reviews summarize earlier research.

At a glance

Latin name

Compound

Phellibaumin A; Daldinone B

Phellibaumin A; Daldinone B

Published in

Molecular & Cellular Toxicology

Molecular & Cellular Toxicology

Covered in Shroom Scan

Section

HEALTH & WELLNESS

HEALTH & WELLNESS

As it ran in Shroom Scan

Liver Cancer Target

Liver Cancer Target

Computational screening identified fungal secondary metabolites—including Phellibaumin A and Daldinone B—that strongly bind to DNA polymerase beta, a key liver cancer enzyme. These compounds showed favorable docking scores, low predicted toxicity, and good drug-like properties. Phellibaumin A stood out as the top candidate, suggesting medicinal mushrooms could yield future therapies against liver cancer.

Computational screening identified fungal secondary metabolites—including Phellibaumin A and Daldinone B—that strongly bind to DNA polymerase beta, a key liver cancer enzyme. These compounds showed favorable docking scores, low predicted toxicity, and good drug-like properties. Phellibaumin A stood out as the top candidate, suggesting medicinal mushrooms could yield future therapies against liver cancer.

New Seizure Research, Reishi Vaccine Boosts, and Fungi Fuel

Shroom Scan · Every Friday

Get Studies Like This, Translated, Every Week

One study a week worth your attention, explained in plain words, plus quick hits, a beginner basic, and a recipe. Free, and one click to leave.